<DOC>
	<DOCNO>NCT02811861</DOCNO>
	<brief_summary>This multicenter , randomize , open-label , Phase 3 study compare efficacy safety lenvatinib combination everolimus ( Arm A ) pembrolizumab ( Arm B ) versus sunitinib ( Arm C ) first-line treatment participant advance renal cell carcinoma .</brief_summary>
	<brief_title>Lenvatinib/Everolimus Lenvatinib/Pembrolizumab Versus Sunitinib Alone Treatment Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histological cytological confirmation renal cell carcinoma ( RCC ) clearcell component At least 1 measurable target lesion accord Response Evaluation Solid Tumors ( RECIST ) 1.1 Karnofsky Performance Status ( KPS ) ≥70 Adequately control blood pressure ( BP ) without antihypertensive medication , define BP ≤150/90 mmHg Screening change antihypertensive medication within 1 week prior Cycle 1/Day 1 ( C1/D1 ) Adequate organ function per blood work Subjects receive systemic anticancer therapy RCC , include antivascular endothelial growth factor ( VEGF ) therapy , systemic investigational anticancer agent Subjects central nervous system ( CNS ) metastases eligible , unless complete local therapy ( eg , whole brain radiation therapy ( WBRT ) , surgery radiosurgery ) discontinue use corticosteroid indication least 4 week start treatment study . Any sign ( eg , radiologic ) symptom brain metastasis must stable least 4 week start study treatment Active malignancy ( except RCC , definitively treat basal squamous cell carcinoma skin , carcinoma insitu cervix bladder ) within past 24 month . Subjects history localize &amp; low risk prostate cancer allow study treat curative intent prostate specific antigen ( PSA ) recurrence within past 5 year Prior radiation therapy within 21 day prior start study treatment exception palliative radiotherapy bone lesion , allow complete 2 week prior study treatment start Received live vaccine within 30 day plan start study treatment Subjects urine protein ≥1 gram/24 hour Fasting total cholesterol &gt; 300 milligram per deciliter ( mg/dL ) ( ˃7.75 millimole per liter ( mmol/L ) ) and/or fast triglyceride level ˃2.5 x upper limit normal ( ULN ) . Note : subject include initiation adjustment lipidlowering medication Uncontrolled diabetes define fast glucose &gt; 1.5 time ULN . Note : subject include initiation adjustment glucoselowering medication Prolongation correct QT ( QTc ) interval &gt; 480 millisecond ( m ) Bleeding thrombotic disorder subject risk severe hemorrhage . The degree tumor invasion/infiltration major blood vessel ( eg , carotid artery ) consider potential risk severe hemorrhage associate tumor shrinkage/necrosis follow lenvatinib therapy Clinically significant hemoptysis tumor bleed within 2 week prior first dose study drug Significant cardiovascular impairment within 6 month first dose study drug : history congestive heart failure great New York Heart Association ( NYHA ) Class II , unstable angina , myocardial infarction stroke , cardiac arrhythmia associate significant cardiovascular impairment , leave ventricular ejection fraction ( LVEF ) institutional normal range determine multiple gated acquisition scan ( MUGA ) echocardiogram Active infection ( infection require systemic treatment ) Human Immunodeficiency Virus ( HIV ) positive Known active Hepatitis B ( eg , Hepatitis B surface antigen ( HBsAg ) reactive ) Hepatitis C ( eg , hepatitis C virus ribonucleic acid ( HCV RNA ) [ qualitative ] detect ) Known history , evidence , interstitial lung disease Has history ( noninfectious ) pneumonitis require steroid , current pneumonitis Subjects diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study treatment . The use physiologic dos corticosteroid ( 7.5 mg/day prednisone equivalent ) may approve consultation sponsor Active autoimmune disease ( exception psoriasis ) require systemic treatment past 2 year ( ie , use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( eg , thyroxine , insulin , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency ) consider form systemic treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Renal Cell Carcinoma ( RCC )</keyword>
	<keyword>Lenvatinib</keyword>
	<keyword>First-line RCC</keyword>
	<keyword>Treatment-naive RCC</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Pembrolizumab</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Phase 3 RCC</keyword>
	<keyword>Phase 3 first-line RCC</keyword>
	<keyword>Phase 3 treatment-naive RCC</keyword>
</DOC>